Bessel
San Francisco, California, United States
Overview
Medtech Scaleup and Rapid Innovation: We help you create the impact that will change lives. We’re not advisors on the sidelines. We embed with your team. We build from within. In medtech, every challenge is a test of systems, leadership, and agility and the teams that win are the ones built to handle all three. Since its inception, Bessel has helped medtech teams go from early concept to market-ready product, with more efficient teams, stronger execution, and systems that compound over time. With three distinct programs—Bessel Rapid Innovation, Powered by Bessel, and Bessel Origin—Bessel supports founders, leaders, and full product teams through every stage of the medtech journey. Commercial scaleup is a call for excellence in rapid innovation to deliver cost reduction, increased reliability & decreased complaints, and improved patient outcomes & clinician experience.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 2
Sector focus
- Biotechnology
- Consulting
- Management Consulting
- Medical Device
- Training
Investment portfolio
- HEARTio
Participated · Seed · Mar 2026
HEARTio’s core product, ECGio, applies deep-learning analysis to standard 12-lead electrocardiograms to predict the presence, severity and location of coronary artery blockages without invasive testing. Early validation work includes a study in the Canadian Journal of Cardiology and a larger JACC Advances study involving more than 16,000 patients that supported the model’s ability to identify coronary artery disease from routine ECGs. The company emphasizes a headless API that uses pre-deployed ECG hardware and integrates software agents to surface subtle abnormalities for clinicians. Leadership includes co-founders Utkars Jain, Adam Butchy and Michael Leasure, with John Marous as Executive Chairman and two co-Chief Commercialisation Officers. HEARTio has public goals to complete a pivotal study, obtain FDA clearance, begin generating revenue, and expand its product suite to additional cardiac indications. The founding story is partly rooted in personal loss, and the team has received recognition including Forbes 30 Under 30.